Sulfasalazine for brain cancer fits
Harald Sontheimer, Richard J Bridges, Harald Sontheimer, Richard J Bridges
Abstract
Recent research has identified an important role for a cystine-glutamate antiporter (system Xc) in the biology of malignant brain tumors. This transporter is effectively inhibited by sulfasalazine, a drug widely used to treat a number of chronic inflammatory conditions such as Crohn's disease. Preclinical data show that sulfasalazine is an effective inhibitor of tumor growth and tumor-associated seizures. These studies suggest that the cystine-glutamate antiporter is a valuable drug target for which tumor-specific drugs can be generated. In the meantime, sulfasalazine may be considered as adjuvant treatment for malignant gliomas.
Conflict of interest statement
Declaration of interest
The authors state no conflict of interest.
Figures
Source: PubMed